Traders should monitor for the upcoming definitive proxy statement and special shareholder meeting date, which will provide details on voting mechanics and timing. A favorable vote would likely lead to closing of the acquisition, taking AVNS private and removing it from public trading.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 23 $24.71entry
- T+1 · 7mo ago −0.20%α −0.99% · $24.66
- T+5 · 7mo ago −0.24%α −1.72% · $24.65
- T+20 · 6mo ago +0.12%α −4.51% · $24.74
- T+60 · 4mo ago +1.13%α −3.89% · $24.99
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Avanos Medical is soliciting shareholder approval for its acquisition by A-AV Holdco I, Inc., an entity affiliated with private equity firm American Industrial Partners (AIP), following a definitive merger agreement signed on April 13, 2026. This DEFA14A filing is part of the proxy process to secure stockholder votes for the transaction, which management positions as a strategic move to accelerate innovation and growth.
Key Financial Metrics
Key Facts
- Avanos Medical, Inc. is being acquired by A-AV Holdco I, Inc., a company affiliated with American Industrial Partners (AIP).
- The merger agreement was signed on April 13, 2026, with shareholder approval being sought via this proxy filing.
- The transaction is structured as a merger with AV MergerSub, Inc., a wholly-owned subsidiary of Parent.
- Shareholders will vote on the proposed acquisition, a material corporate event requiring formal proxy solicitation under SEC rules.
- Management, led by CEO David Pacitti, frames the deal as a strategic acceleration of innovation, investment, and growth.
Financial Impact
Transaction represents a full acquisition of Avanos, a $1.1B market cap company, though the specific deal value is not disclosed in this filing.
Risk Factors
- Risk that closing conditions are not satisfied or waived, delaying or derailing the transaction.
- Possibility of competing bids emerging, given the lack of disclosed termination fee specifics.
- Potential termination of the merger agreement under circumstances requiring Avanos to pay a termination fee.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001606498-26-000055 |
| Document: 0001606498-26-000055-index-headers.html | 0001606498-26-000055 |
| Document: 0001606498-26-000055-index.html | 0001606498-26-000055 |
| Document: 0001606498-26-000055.txt | 0001606498-26-000055 |
Track record
7 reports on AVNS
The track record builds as more bullish or bearish reports settle.
Filters
- Jul 27, 202616w ago 25-NSE Neutral 5/10 Entry $24.99 No price data
- Jul 2, 202619w ago 8-K / DEFA14A Bullish 7/10 Entry $24.93 to $24.94 ▲ +0.04% −0.89% vs SPY
- Jun 10, 202622w ago DEFM14A Bullish 8/10 Entry $24.98 to $24.87 ▼ −0.44% −0.87% vs SPY
- May 5, 202627w ago DEFA14A Neutral 5/10 Entry $24.72 to $24.73 ▲ +0.04% −1.09% vs SPY
- Apr 23, 202629w ago DEFA14A Bullish 8/10 Viewing Entry $24.71 to $24.65 ▼ −0.24% −1.72% vs SPY
- Apr 14, 202630w ago DEFA14A Neutral 4/10 Entry $24.63 to $24.64 ▲ +0.04% −1.35% vs SPY
- Feb 26, 202637w ago 8-K Neutral 5/10 Entry $14.49 to $13.79 ▼ −4.83% −3.70% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers